Skip to main content

Advertisement

SpringerLink
Log in

Myocardial infarction in a patient with migraine and triptan overuse treated with anti-CGRP receptor monoclonal antibody: a case report

  • Letter to the Editors
  • Published:
Journal of Neurology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Tepper S, Ashina M, Reuter U et al (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16:425–434

    Article  CAS  Google Scholar 

  2. Ho TW, Edvinsson L, Goadsby PJ (2010) CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol 6:573–582

    Article  CAS  Google Scholar 

  3. Brain SD, Williams TJ, Tippins JR, Morris HR, MacIntyre I (1985) Calcitonin gene-related peptide is a potent vasodilator. Nature 313:54–56

    Article  CAS  Google Scholar 

  4. Aradi S, Kaiser E, Cucchiara B (2019) Ischemic stroke associated with calcitonin gene-related peptide inhibitor therapy for migraine: a case report. J Stroke Cerebrovasc Dis Off J Natl Stroke Assoc 28:104286

    Article  Google Scholar 

  5. Rozen TD, Bhatt AA (2021) Reversible cerebral vasoconstriction syndrome developing after an erenumab injection for migraine prevention. Cephalalgia Int J Headache. https://doi.org/10.1177/03331024211037277 (Epub 2021 Aug 18)

    Article  Google Scholar 

  6. Dodick DW, Tepper SJ, Ailani J et al (2021) Risk of hypertension in erenumab-treated patients with migraine: analyses of clinical trial and postmarketing data. Headache 61:1411–1420

    Article  Google Scholar 

  7. Depre C, Antalik L, Starling A et al (2018) A randomized, double-blind, placebo-controlled study to evaluate the effect of erenumab on exercise time during a treadmill test in patients with stable angina. Headache 58:715–723

    Article  Google Scholar 

  8. Kee Z, Kodji X, Brain SD (2018) The role of calcitonin gene related peptide (CGRP) in neurogenic vasodilation and its cardioprotective effects. Front Physiol 9:1249

    Article  Google Scholar 

  9. Mishima T, Ito Y, Hosono K et al (2011) Calcitonin gene-related peptide facilitates revascularization during hindlimb ischemia in mice. Am J Physiol Heart Circ Physiol 300:H431-439

    Article  CAS  Google Scholar 

  10. Kumar A, Potts JD, DiPette DJ (2019) Protective role of α-calcitonin gene-related peptide in cardiovascular diseases. Front Physiol 10:821

    Article  Google Scholar 

  11. Sacco S, Bendtsen L, Ashina M et al (2019) European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain 20:6

    Article  Google Scholar 

  12. Dodick DW, Papademetriou V (2004) Cardiovascular safety of triptans. Cephalalgia Int J Headache 24:513–514

    Article  CAS  Google Scholar 

  13. Albieri V, Olsen TS, Andersen KK (2016) Risk of stroke in migraineurs using triptans. Associations with age, sex, stroke severity and subtype. EBioMedicine 6:199–205

    Article  Google Scholar 

  14. Wackenfors A, Jarvius M, Ingemansson R, Edvinsson L, Malmsjö M (2005) Triptans induce vasoconstriction of human arteries and veins from the thoracic wall. J Cardiovasc Pharmacol 45:476–484

    Article  CAS  Google Scholar 

  15. Barra S, Lanero S, Madrid A et al (2010) Sumatriptan therapy for headache and acute myocardial infarction. Expert Opin Pharmacother 11:2727–2737

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Via Olgettina, 60, 20132, Milan, Italy

    I. Cetta, R. Messina, B. Colombo & M. Filippi

  2. Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy

    I. Cetta, R. Messina & M. Filippi

  3. Vita-Salute San Raffaele University, Milan, Italy

    I. Cetta & M. Filippi

Authors
  1. I. Cetta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Messina
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Colombo
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Filippi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R. Messina.

Ethics declarations

Conflicts of interest

None declared in relation to this manuscript.

Ethical approval

The patient provided informed consent for this publication.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cetta, I., Messina, R., Colombo, B. et al. Myocardial infarction in a patient with migraine and triptan overuse treated with anti-CGRP receptor monoclonal antibody: a case report. J Neurol 269, 5170–5172 (2022). https://doi.org/10.1007/s00415-022-11128-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-022-11128-5

Search

Navigation